Barrow, Hanley, Mewhinney & Strauss’s Meridian Bioscience Inc VIVO Stock Holding History

Barrow, Hanley, Mewhinney & Strauss’s Portfolio VIVO Stock Details VIVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-134,081	Closed	-$2M	–	412
2018 Q3	$2M	Sell	134,081 -14,867	-10%	-$231K	﹤0.01%	268
2018 Q2	$2.37M	Hold	148,948	–	–	﹤0.01%	270
2018 Q1	$2.12M	Sell	148,948 -441	-0.3%	-$6.53K	﹤0.01%	271
2017 Q4	$2.09M	Sell	149,389 -91	-0.1%	-$1.33K	﹤0.01%	273
2017 Q3	$2.14M	Sell	149,480 -661	-0.4%	-$9.44K	﹤0.01%	264
2017 Q2	$2.37M	Buy	150,141 +142,536	+1,874%	+$2.05M	﹤0.01%	257
2017 Q1	$105K	Buy	+7,605	New	+$106K	﹤0.01%	331

Other funds holding VIVO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

SFM

Systematic Financial Management Teaneck, New Jersey $4.36B AUM 40.56% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss's VIVO Position: Q4 2018 in Review

Barrow, Hanley, Mewhinney & Strauss sold out of Meridian Bioscience Inc (VIVO) in Q4 2018, closing a stake of 134,081 shares — an estimated $2M sold.

Barrow, Hanley, Mewhinney & Strauss first reported a position in VIVO in Q1 2017 and held it in 7 quarters. The position peaked at $2.37M in Q2 2018. 191 funds tracked by Wall St. Rank hold VIVO as of Q4 2018.

Barrow, Hanley, Mewhinney & Strauss reported no remaining Meridian Bioscience Inc position as of Q4 2018 after selling out during the quarter.
Barrow, Hanley, Mewhinney & Strauss sold 134,081 Meridian Bioscience Inc shares in Q4 2018, an estimated $2M.
Barrow, Hanley, Mewhinney & Strauss first reported a position in Meridian Bioscience Inc in Q1 2017 and held it in 7 quarters.
Barrow, Hanley, Mewhinney & Strauss's Meridian Bioscience Inc position peaked at $2.37M in Q2 2018.
191 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q4 2018.

Based on Barrow, Hanley, Mewhinney & Strauss's 13F filing for Q4 2018, filed 13 Feb 2019.